相似文献
1
Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing.
Front Cell Infect Microbiol. 2021 May 17;11:684515. doi: 10.3389/fcimb.2021.684515. eCollection 2021.
3
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews.
Cochrane Database Syst Rev. 2017 Sep 7;9(9):CD012252. doi: 10.1002/14651858.CD012252.pub2.
5
FDA-approved drugs for targeting virulence of Pseudomonas aeruginosa: A drug repurposing approach to combat multidrug resistance.
Microb Pathog. 2025 Sep;206:107781. doi: 10.1016/j.micpath.2025.107781. Epub 2025 Jun 3.
7
Intracavity lavage and wound irrigation for prevention of surgical site infection.
Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD012234. doi: 10.1002/14651858.CD012234.pub2.
8
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.
Cochrane Database Syst Rev. 2025 Jan 20;1(1):CD009730. doi: 10.1002/14651858.CD009730.pub3.
9
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
10
Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care.
Cochrane Database Syst Rev. 2022 Oct 17;10(10):CD010130. doi: 10.1002/14651858.CD010130.pub3.
引用本文的文献
1
Beyond One-Size-Fits-All: Addressing Methodological Constraints in Novel Antimicrobials Discovery.
Antibiotics (Basel). 2025 Aug 21;14(8):848. doi: 10.3390/antibiotics14080848.
2
Employing diclofenac sodium as a novel therapeutic frontier for Staphylococcus epidermidis infections.
Sci Rep. 2025 Aug 26;15(1):31377. doi: 10.1038/s41598-025-14316-1.
3
Proteomic Insights into Bacterial Responses to Antibiotics: A Narrative Review.
Int J Mol Sci. 2025 Jul 27;26(15):7255. doi: 10.3390/ijms26157255.
4
Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.
RSC Adv. 2025 Jul 14;15(30):24450-24474. doi: 10.1039/d5ra04047g. eCollection 2025 Jul 10.
5
Antimicrobial Efficacy of Nd:YAG Laser in Polymicrobial Root Canal Infections: A Systematic Review of In Vitro Studies.
Int J Mol Sci. 2025 Jun 12;26(12):5631. doi: 10.3390/ijms26125631.
6
Strategic re-engineering of antibiotics.
Nat Rev Bioeng. 2025 Mar;3(3):213-229. doi: 10.1038/s44222-024-00250-w. Epub 2024 Oct 15.
7
Organoselenium compounds as an enriched source for the discovery of new antimicrobial agents.
RSC Med Chem. 2025 Apr 7. doi: 10.1039/d4md00677a.
8
Synthesis and Biological Evaluation of Bicyclic Pyrazolines with Promising Antimicrobial Activities.
ChemMedChem. 2025 Jul 18;20(14):e202500144. doi: 10.1002/cmdc.202500144. Epub 2025 May 27.
9
Insight into antistaphylococcal effect of chlorinated 1-hydroxynaphthalene-2-carboxanilides.
ADMET DMPK. 2025 Mar 26;13(2):2684. doi: 10.5599/admet.2684. eCollection 2025.
10
A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.
Antibiotics (Basel). 2025 Feb 21;14(3):221. doi: 10.3390/antibiotics14030221.
本文引用的文献
1
It's Time to Reverse our Thinking: The Reverse Translation Research Paradigm.
Clin Transl Sci. 2018 Mar;11(2):98-99. doi: 10.1111/cts.12538. Epub 2018 Feb 9.
2
Old Compounds, New Uses, New Ways: Many Ways.
Assay Drug Dev Technol. 2017 Dec;15(8):353. doi: 10.1089/adt.2017.29067.hmu.
3
The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016.
JAMA. 2017 Dec 5;318(21):2137-2138. doi: 10.1001/jama.2017.14896.
4
Reverse Translation in Advancing Pharmacotherapy in Pediatric Rheumatology: A Logical Approach in Rare Diseases with Limited Resources.
Clin Transl Sci. 2018 Mar;11(2):106-108. doi: 10.1111/cts.12513. Epub 2017 Nov 28.
5
Repurposing Statins for Renal Protection: Is It a Class Effect?
Clin Transl Sci. 2018 Mar;11(2):100-102. doi: 10.1111/cts.12521. Epub 2017 Nov 15.
6
Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
J Antibiot (Tokyo). 2017 Dec;70(12):1087-1096. doi: 10.1038/ja.2017.124. Epub 2017 Nov 1.
7
Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections.
Am J Law Med. 2016 May;42(2-3):429-450. doi: 10.1177/0098858816658275.
8
Optimized efflux assay for the NorA multidrug efflux pump in Staphylococcus aureus.
J Microbiol Methods. 2017 Nov;142:39-40. doi: 10.1016/j.mimet.2017.09.001. Epub 2017 Sep 5.
9
Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
BMJ. 2017 Sep 7;358:j3837. doi: 10.1136/bmj.j3837.
10
Non-antibiotic treatment for infectious diseases.
Rev Esp Quimioter. 2017 Sep;30 Suppl 1:66-71.
Zotero 插件